Related Experiment Video

Updated: Dec 18, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.3K

Novel biomarkers for the management of chronic hepatitis B

Takako Inoue1, Yasuhito Tanaka1,2,3

  • 1Department of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya, Japan.

Clinical and Molecular Hepatology
|June 16, 2020
PubMed

Insights

Novel biomarkers like HBcrAg and M2BPGi aid in managing chronic hepatitis B (CHB) by assessing viral activity and liver fibrosis. These markers, including AFP combinations, help predict and diagnose hepatocellular carcinoma (HCC) development and recurrence.

Area of Science:

  • Hepatology and Viral Immunology
  • Biomarker Discovery and Diagnostics

Background:

  • Chronic hepatitis B (CHB) poses risks of cirrhosis and hepatocellular carcinoma (HCC) due to persistent Hepatitis B virus (HBV) cccDNA.
  • Effective CHB management requires monitoring viral activity and liver fibrosis to prevent HCC progression.

Purpose of the Study:

  • To review novel serum biomarkers for managing CHB.
  • To highlight markers for assessing intrahepatic viral replicative activity, liver fibrosis, and HCC development/prognosis.

Main Methods:

  • Review of current literature on HBV biomarkers.
  • Analysis of Hepatitis B core-related antigen (HBcrAg) for viral activity and HCC prediction.
  • Evaluation of Mac-2 binding protein glycosylation isomer (M2BPGi) for liver fibrosis assessment.

Main Results:

  • HBcrAg levels correlate with HBV DNA and cccDNA, predicting HCC occurrence/recurrence even with undetectable HBV DNA or HBsAg loss.
  • Elevated M2BPGi indicates liver fibrosis and predicts HCC development in CHB patients.
  • Novel markers like Dickkopf-1 and specific AFP combinations show promise for improved HCC diagnosis.

Conclusions:

  • HBcrAg and M2BPGi are valuable noninvasive biomarkers for CHB management.
  • Combined biomarkers offer enhanced accuracy for diagnosing and predicting HCC in CHB patients.
  • These novel markers improve the clinical strategy for preventing HBV-related liver disease progression.

Keywords:
Alpha-fetoproteinHepatitis B core-related antigenLens culinaris agglutinin-reactive fraction of alpha-fetoproteinMac 2-binding protein glycan isomerProtein induced by vitamin K absence or antagonist-II

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.8K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

7.0K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
116
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
425
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
213
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
148